Arrowhead Pharma (ARWR) PT Raised at Piper Sandler Following FDA Approval
Tweet Send to a Friend
Piper Sandler analyst Edward A. Tenthoff raised the price target on Arrowhead Pharma (NASDAQ: ARWR) to $70.00 (from $45.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
